Drug Target Review2024-05-22T12:00:53
The world’s first generation of human BBB organoids from hPSCs accurately replicated features of cerebral cavernous malformation.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-11-16T07:00:00Z
Author Dr Martin Baraibar
2026-11-13T07:00:00Z
Contributor Dr Panos Roussos, Drug Target Review
2026-07-31T06:00:00
Contributor Dr Davinder Ramsingh, Drug Target Review
2026-10-21T15:00:00
Sponsored by Oxford Nanopore Technologies
2026-08-27T08:48:00
Sponsored by Danaher
2026-10-21T14:02:00
Contributor Jim Corbett, Drug Target Review
2026-07-08T07:58:00
Contributor Dr Nick Lynch, Dr Raminderpal Singh
2026-05-12T09:31:00
Contributor Sugish Pillai, Axel Ziemke and Dr Gary Kusdian
Site powered by Webvision Cloud